SELLAS Life Sciences Group, Inc.Company Review & Valuation

SLS
Nasdaq
Latest Price
2.58USD
Market Capitalization
17.33mUSD

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agenShow moret, which has completed Phase II clinical trials for the treatment of acute myeloid leukemia and malignant pleural mesothelioma; is in Phase II clinical trials to treat multiple myeloma; and is in various development phases as a potential treatment for ovarian cancer. It also develops NeuVax that is in Phase II clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which have completed early stage trials in ovarian, endometrial, and breast cancers; and GALE-401, an anagrelide controlled release that has completed Phase II clinical trials in patients with essential thrombocythemia, as well as for the treatment of elevated platelets in patients with myeloproliferative neoplasms. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Show less

Industry
Biotechnology
HQ Location
New York, New York

Stock Price

Price data not available for SELLAS Life Sciences Group, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Arena Pharmaceuticals
Biofrontera
Valneva
argenx

back to top